Scheinberg Lab

Developing cutting-edge therapeutics for cancer treatment @sloan_kettering.
Tweets are from lab members, not from Dr. Scheinberg, unless signed -DAS.

[Ursula Bourne @engineer_ursula]

Congratulations to my husband, Dr. Bourne!! @TheBourneImmuno I'm so proud of you. It's an honor to be along for the ride.

[Mamadou A. Bah @M_AlphaBah]

Congratulations to Dr. Bourne (@TheBourneImmuno) my younger big brother for an incredible thesis today! You’re truly an inspirational person in and out of the lab. A phenomenal scientist, dedicated DEI activist, and a monster of a cyclist! UPenn is incredibly lucky to have you!

[Scheinberg Lab @DASLab_MSKCC]

A huge congratulations to @TheBourneImmuno on his recent thesis defense! You've done phenomenal work, and we look forward to your future success. You will be great missed!

[Scheinberg Lab @DASLab_MSKCC]

https://t.co/YbiUN4ITMz

[Scheinberg Lab @DASLab_MSKCC]

Congratulations to Megan Dacek (@deg_macek) and Keifer Kurtz (@KeiferKurtz) on their recent Blood submission "Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker". Years of hard work have led to this therapeutic advancement.

[Scheinberg Lab @DASLab_MSKCC]

Welcome to the lab and to Twitter @stephani0713! We are excited to see the awesome work you will do.

[Dr. Christopher Bourne (he/him) @TheBourneImmuno]

Hello Science Twitter! Please join me in welcoming @stephani0713 to the Sci Twitter sphere! She is a @TriIMDPhD student rotating in the @DASLab_MSKCC with me! She is also a soon-to-be @BlackinCancer member! 🌟🌟

[Sebastian Chung @SebastianChung0]

Fantastic talk by @emma_reynaud99 wrapping up months of amazing work imaging CAR T cells in action diagnosing & treating cancers @MSKCancerCenter @LabKrebs @DASLab_MSKCC @SchuringaJan Larsonlab #theranostics

[Scheinberg Lab @DASLab_MSKCC]

Congratulations to Dr. Heather Jones on her successful thesis defense today!! She delivered an outstanding presentation. Be on the lookout for her upcoming study on TCR cross-reactivity.

[Scheinberg Lab @DASLab_MSKCC]

Congratulations to former fellow @MgKlatt on this groundbreaking publication! Using Mass Spec, we identify a novel target, NDC80, and target it with TCR mimic antibodies.

[Martin Klatt @MgKlatt]

I am celebrating! My 11th paper from my postdoc-time at the amazing @DASLab_MSKCC Lab is now out @BloodJournal. I thank all fantastic collaborators for their support but especially @EurekaThera for their help and unlimited enthusiasm for TCRmimics.
https://t.co/FGjDv3jqn8 1/2

[Scheinberg Lab @DASLab_MSKCC]

ROCK STAR! Check out this article on our grad student @TheBourneImmuno on his recent Sawyers fellowship award!

A Young Scientist Earns MSK Fellowship: Here’s When He Had His ‘Aha’ Moment https://t.co/1MMcClff8t

[Thomas Gardner @TJJardinero]

Excited to share my work from @DASLab_MSKCC lab out today in @nchembio where we develop CAR-T cells that produce small molecule drugs at the tumor site. This is an exciting step forward in the utilization of engineered cells for drug delivery! https://t.co/zuR7qs2JIr

[Dr. Christopher Bourne (he/him) @TheBourneImmuno]

Stay tuned! This is a massive collaboration across multiple labs and disciplines at @sloan_kettering @WeillCornellGS @WeillCornell !!

[Dr. Christopher Bourne (he/him) @TheBourneImmuno]

One critique of this platform that uses bacterial enzymes is that host immune responses will reject it. In my thesis work, I adapt this project in fully immunocompetent mouse models. We've had very promising efficacy results so far!

[Dr. Christopher Bourne (he/him) @TheBourneImmuno]

In our @DASLab_MSKCC paper we demonstrate that T cells can be engineered to release small molecule chemotherapies at the tumor site. We do this using bacterial enzymes. In the current paper, we use immunodeficient mouse models as a human proof of concept.

[Dr. Christopher Bourne (he/him) @TheBourneImmuno]

2.5 years of revision and over 5 years of collaborative work, CONGRATULATIONS to @TJJardinero , @DASLab_MSKCC and all others who contributed to this manuscript 🎉🎉🥳🥳. This novel platform will change adoptive T cell therapy.

My thesis work will build on this. More info 👇🏾👇🏾👇🏾

[Scheinberg Lab @DASLab_MSKCC]

Congratulations @TJJardinero and our collaborators in the Tan lab for this awesome work! We show how adoptive T cell therapies like CAR T cells can be used to deliver small-molecule drugs to tumors. This is the first manuscript of many to come on this project.

[Thomas Gardner @TJJardinero]

Excited to share my work from @DASLab_MSKCC lab out today in @nchembio where we develop CAR-T cells that produce small molecule drugs at the tumor site. This is an exciting step forward in the utilization of engineered cells for drug delivery! https://t.co/zuR7qs2JIr

[Scheinberg Lab @DASLab_MSKCC]

Congratulations to @PedroCSilberman on winning First Place at the @WeillCornellGS 3 minute thesis contest!

[Scheinberg Lab @DASLab_MSKCC]

Congratulations to our student @TheBourneImmuno on receiving this transitional fellowship. Well deserved we are all very proud of you! 🎉🎉

[Dr. Christopher Bourne (he/him) @TheBourneImmuno]

It comes full circle! 🥳🥳I've been selected as the inaugural MSK MERIT Sawyers fellow! This provides 5 years of funding, 2 as a student, and 3 as a post doc!💸💰

Thank you to @MSKEducation and the Sawyers family for their commitment to diversity and my career growth. ❤🤩

[Scheinberg Lab @DASLab_MSKCC]

Congratulations to @LeilaPeraro2 on publishing this story in @MolTherapy! We show that CAR T cells generate humoral immune responses in patients and we engineer them to secrete antibody-cleaving enzymes.

[Cell Therapy News @celltherapynews]

Dr. David Scheinberg's team (@DASLab_MSKCC) at @sloan_kettering and @EinsteinMed utilized the IgG protease “IdeS” to reprogram CAR T cells to defeat humoral #immune attacks ⚔️.
https://t.co/mNKyids6cd

[Scheinberg Lab @DASLab_MSKCC]

Congratulations to our former MD-PhD student @freddyeescorcia on receiving the Lasker Clinical Scholar award! This award provides up to 10 years funding from the NIH intramural program. Well deserved!